Literature DB >> 15708853

Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II Transforming growth factor-{beta} receptor (T{beta}RII{delta}k).

Christopher P Denton1, Gisela E Lindahl, Korsa Khan, Xu Shiwen, Voon H Ong, Nicholas J Gaspar, Konstantinos Lazaridis, Dylan R Edwards, Andrew Leask, Mark Eastwood, Patricia Leoni, Elisabetta A Renzoni, George Bou Gharios, David J Abraham, Carol M Black.   

Abstract

We have generated transgenic mice expressing a kinase-deficient type II transforming growth factor-beta (TGFbeta) receptor selectively on fibroblasts (TbetaRIIDeltak-fib). These mice develop dermal and pulmonary fibrosis. In the present study we explore activation of TGFbeta signaling pathways in this strain and examine the profibrotic properties of explanted transgenic fibroblasts including myofibroblast differentiation and abnormal metalloproteinase production. Gene expression profiles of littermate wild type or transgenic fibroblasts were compared using high-density gene arrays and validated by Taqman reverse transcriptase-PCR, Northern and Western blotting. Using a specific inhibitor (SD-208) we demonstrate that the abnormal phenotype of these cells is dependent upon TbetaRI kinase (ALK5) activity, and that transgenic fibroblasts show enhanced expression and activation of TGFbeta together with increased levels of wild type TbetaRII. Moreover, we confirm that transgene expression is itself regulated by TGFbeta and that expression at low levels facilitates signaling, whereas high level expression is inhibitory. For a subset of TGFbeta responsive genes basal up-regulation is normalized or suppressed by exogenous recombinant TGFbeta1 at time points coincident with increased transgene expression. These findings explain the profound refractoriness of TbetaRIIDeltak-fib fibroblasts to exogenous TGFbeta1, despite their activated phenotype. Thus, transgenic fibroblasts recapitulate many hallmark biochemical properties of fibrotic cells, including high level CTGF (CCN2) expression and type I collagen overproduction, altered MMP production, and myofibroblast differentiation. These cells also show an enhanced ability to contract collagen gel matrices. Our study demonstrates that altered high affinity TGFbeta receptor function may lead to ligand-dependent activation of downstream signaling, and provides further evidence of a pivotal role for sustained TGFbeta overactivity in fibrosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15708853     DOI: 10.1074/jbc.M413134200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  Evolving concepts of apoptosis in idiopathic pulmonary fibrosis.

Authors:  Victor J Thannickal; Jeffrey C Horowitz
Journal:  Proc Am Thorac Soc       Date:  2006-06

2.  siRNA-targeting transforming growth factor-β type I receptor reduces wound scarring and extracellular matrix deposition of scar tissue.

Authors:  Yi-Wen Wang; Nien-Hsien Liou; Juin-Hong Cherng; Shu-Jen Chang; Kuo-Hsing Ma; Earl Fu; Jiang-Chuan Liu; Niann-Tzyy Dai
Journal:  J Invest Dermatol       Date:  2014-02-13       Impact factor: 8.551

3.  CD8+ T cells in systemic sclerosis.

Authors:  Patrizia Fuschiotti
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

Review 4.  PAI-1 in tissue fibrosis.

Authors:  Asish K Ghosh; Douglas E Vaughan
Journal:  J Cell Physiol       Date:  2012-02       Impact factor: 6.384

Review 5.  Systemic sclerosis: a prototypic multisystem fibrotic disorder.

Authors:  John Varga; David Abraham
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

Review 6.  Interstitial lung disease in connective tissue disease--mechanisms and management.

Authors:  Athol U Wells; Christopher P Denton
Journal:  Nat Rev Rheumatol       Date:  2014-09-30       Impact factor: 20.543

7.  Systemic vasculopathy with altered vasoreactivity in a transgenic mouse model of scleroderma.

Authors:  Emma C Derrett-Smith; Audrey Dooley; Korsa Khan; Xu Shi-wen; David Abraham; Christopher P Denton
Journal:  Arthritis Res Ther       Date:  2010-04-15       Impact factor: 5.156

Review 8.  Animal models of systemic sclerosis: their utility and limitations.

Authors:  Carol M Artlett
Journal:  Open Access Rheumatol       Date:  2014-07-01

9.  Pathogenesis of systemic sclerosis associated interstitial lung disease.

Authors:  Svetlana I Nihtyanova; Christopher P Denton
Journal:  J Scleroderma Relat Disord       Date:  2020-03-05

Review 10.  Therapeutic targets in systemic sclerosis.

Authors:  Christopher P Denton
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.